Clinical impact of frailty on treatment outcomes of elderly patients with relapsed and/or refractory multiple myeloma treated with lenalidomide plus dexamethasone
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Ho Sup | - |
dc.contributor.author | Kim, Kihyun | - |
dc.contributor.author | Lee, Je-Jung | - |
dc.contributor.author | Yoon, Sung-Soo | - |
dc.contributor.author | Bang, Soo-Mee | - |
dc.contributor.author | Kim, Jin Seok | - |
dc.contributor.author | Eom, Hyeon-Seok | - |
dc.contributor.author | Yoon, Dok Hyun | - |
dc.contributor.author | Lee, Yoojin | - |
dc.contributor.author | Shin, Ho-Jin | - |
dc.contributor.author | Park, Yong | - |
dc.contributor.author | Jo, Jae-Cheol | - |
dc.contributor.author | Lee, Won Sik | - |
dc.contributor.author | Do, Young Rok | - |
dc.contributor.author | Mun, Yeung-Chul | - |
dc.contributor.author | Lee, Mark Hong | - |
dc.contributor.author | Kim, Hyo Jung | - |
dc.contributor.author | Kim, Sung-Hyun | - |
dc.contributor.author | Kim, Min Kyoung | - |
dc.contributor.author | Lim, Sung-Nam | - |
dc.contributor.author | Park, Seong Kyu | - |
dc.contributor.author | Yi, Jun Ho | - |
dc.contributor.author | Lee, Jae Hoon | - |
dc.contributor.author | Min, Chang-Ki | - |
dc.date.accessioned | 2021-09-10T06:26:25Z | - |
dc.date.available | 2021-09-10T06:26:25Z | - |
dc.date.issued | 2021-01 | - |
dc.identifier.issn | 0925-5710 | - |
dc.identifier.issn | 1865-3774 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/19051 | - |
dc.description.abstract | We compared efficacy and safety, according to frailty, of elderly patients with relapsed and refractory multiple myeloma (RRMM) treated with lenalidomide and dexamethasone (Rd), for whom bortezomib treatment had failed. Patients, 164 (52.9%) and 146 (47.1%), were classified as non-frail and frail using a simplified frailty scale. The overall response rates (ORR) and survival outcomes were lower in frail than in non-frail patients (ORR: 56.2% vs. 67.7%,P = 0.069; median progression free survival: 13.17 vs. 17.80 months,P = 0.033; median overall survival: 23.00 vs. 36.27 months,P = 0.002, respectively). The number of treatment emergent adverse events in grade 3 or worse was higher in frail than in non-frail patients (41.8% vs. 24.4%,P = 0.002, respectively). In frail patients, independent poor prognostic factors for survival were two or more Charlson comorbidity index (CCI) score, prior to exposure to both bortezomib and thalidomide, and achieved less than partial response In conclusion, frailty could predict clinical outcomes of Rd treatment in elderly patients with RRMM who had failed prior bortezomib. In frail patients, lower CCI in addition to less previous treatment exposure and deep response were associated with better survival. | - |
dc.format.extent | 11 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Japanese Society of Hematology | - |
dc.title | Clinical impact of frailty on treatment outcomes of elderly patients with relapsed and/or refractory multiple myeloma treated with lenalidomide plus dexamethasone | - |
dc.type | Article | - |
dc.publisher.location | 일본 | - |
dc.identifier.doi | 10.1007/s12185-020-02988-6 | - |
dc.identifier.scopusid | 2-s2.0-85090196162 | - |
dc.identifier.wosid | 000566332800002 | - |
dc.identifier.bibliographicCitation | International Journal of Hematology, v.113, no.1, pp 81 - 91 | - |
dc.citation.title | International Journal of Hematology | - |
dc.citation.volume | 113 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 81 | - |
dc.citation.endPage | 91 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Hematology | - |
dc.relation.journalWebOfScienceCategory | Hematology | - |
dc.subject.keywordPlus | GERIATRIC ASSESSMENT | - |
dc.subject.keywordPlus | CONSENSUS | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordAuthor | Elderly multiple myeloma | - |
dc.subject.keywordAuthor | Relapsed and refractory | - |
dc.subject.keywordAuthor | Lenalidomide and dexamethasone | - |
dc.subject.keywordAuthor | Frailty | - |
dc.subject.keywordAuthor | Survival | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.